Sana biotechnology, inc. SANA.US Overview
SANA AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
SANA Current Performance
-0.95%
Sana biotechnology, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
SANA Key Information
SANA Revenue by Segments
Browsing restrictions can be lifted for a fee.
SANA Net Income
Browsing restrictions can be lifted for a fee.
SANA Cash Flow
Browsing restrictions can be lifted for a fee.
SANA Profit Margin
Browsing restrictions can be lifted for a fee.
SANA PE Ratio River
Browsing restrictions can be lifted for a fee.
SANA Financial Forecast
Browsing restrictions can be lifted for a fee.
SANA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
SANA Profile
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Price of SANA
SANA FAQ
When is SANA's latest earnings report released?
The most recent financial report for Sana biotechnology, inc. (SANA) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SANA's short-term business performance and financial health. For the latest updates on SANA's earnings releases, visit this page regularly.
How much debt does SANA have?
As of the end of the reporting period, Sana biotechnology, inc. (SANA) had total debt of 91.31M, with a debt ratio of 0.2. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does SANA have?
At the end of the period, Sana biotechnology, inc. (SANA) held Total Cash and Cash Equivalents of 100.33M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is SANA's EPS continuing to grow?
According to the past four quarterly reports, Sana biotechnology, inc. (SANA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.21. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of SANA?
Sana biotechnology, inc. (SANA)'s Free Cash Flow (FCF) for the period is -48.54M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 40.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.